IIT researchers find new molecule that can be used as targeted therapy to treat prostate cancer
The molecule has shown potency in cells to completely reduce tumour in 50 days.
By PTI | Updated:
iStock
NEW DELHI: Researchers at the Indian Institute of Technology (IIT), Gandhinagar, claim to have discovered a new molecule which can be used as a targeted therapy for prostate cancer. The research in collaboration with scientists at Louisiana State University Health Center, USA and the University of Manchester, has also been published in international journal "Cell Press, iScience".
According to Sivapriya Kirubakaran, Professor at IIT Gandhinagar, who led the research, about 5.56 lakh Indians die of cancer every year, and the increasing resistance to anti-cancer drugs is also of grave concern.
"Prostate cancer, the second most commonly occurring cancer in men worldwide needs a hormone called 'androgen' to grow. The standard treatment method is hormonal therapy or androgen-deprivation therapy (ADT) which provides respite from disease progression. However, it could fail when cancer spreads to other parts of the body leading to a terminal phase of the disease," Kirubakaran told .
"We have discovered a new molecule called J54 which has shown great potency not only in cells but also in animals (mice model) to completely reduce tumour (prostate cancer) in 50 days (in male mice). The median time for prostate cancer to shrink in human male patients is about 18 months, some quicker, some slower, depending on the size of tumour detected," she added.
Sivapriya further explained that this molecule is the first selective inhibitor of the protein that causes cancer initiation and growth, mainly in the prostate.
"Since J54 combination therapy is targeted to a specific protein, it is expected to be more effective and personalised for the treatment of a particular patient. It has not shown any side effects or toxicity effects in normal cells and animals. The new molecule completely reduces prostate cancer in mice model.
"Also, the amount of drug used is considerably reduced when compared to known therapy. The efficacy and potency shown by J54 molecule create hope for a faster therapy of prostate cancer. The scientists are confident that the findings pave the way for a new targeted therapy for prostate cancer with fewer side effects, if proved successful in clinical and human trials," she added.
Among various diseases prevalent in the country, cancer is known as one of the leading causes of mortality and morbidity in the country. As per Indian population census data, the rate of mortality due to cancer in India is high and alarming in people below the age of 70.
Cancer is the second most common disease in India responsible for maximum mortality with about 0.3 million deaths per year. This is owing to the lack of awareness on the types of cancer, need for early diagnosis and treatment of the disease. Of the types of cancer in India, breast, cervix, colon and prostate cancer are most common and hence knowing its signs and symptoms is key to the management.
Dr Bhavna Parikh, Consultant Medical Oncologist of Bombay Hospital shares details about each of these cancers.
According to Sivapriya Kirubakaran, Professor at IIT Gandhinagar, who led the research, about 5.56 lakh Indians die of cancer every year, and the increasing resistance to anti-cancer drugs is also of grave concern.
"Prostate cancer, the second most commonly occurring cancer in men worldwide needs a hormone called 'androgen' to grow. The standard treatment method is hormonal therapy or androgen-deprivation therapy (ADT) which provides respite from disease progression. However, it could fail when cancer spreads to other parts of the body leading to a terminal phase of the disease," Kirubakaran told .
"We have discovered a new molecule called J54 which has shown great potency not only in cells but also in animals (mice model) to completely reduce tumour (prostate cancer) in 50 days (in male mice). The median time for prostate cancer to shrink in human male patients is about 18 months, some quicker, some slower, depending on the size of tumour detected," she added.
Sivapriya further explained that this molecule is the first selective inhibitor of the protein that causes cancer initiation and growth, mainly in the prostate.
"Since J54 combination therapy is targeted to a specific protein, it is expected to be more effective and personalised for the treatment of a particular patient. It has not shown any side effects or toxicity effects in normal cells and animals. The new molecule completely reduces prostate cancer in mice model.
ADVERTISEMENT
"Also, the amount of drug used is considerably reduced when compared to known therapy. The efficacy and potency shown by J54 molecule create hope for a faster therapy of prostate cancer. The scientists are confident that the findings pave the way for a new targeted therapy for prostate cancer with fewer side effects, if proved successful in clinical and human trials," she added.
Cancer is the second most common disease in India responsible for maximum mortality with about 0.3 million deaths per year. This is owing to the lack of awareness on the types of cancer, need for early diagnosis and treatment of the disease. Of the types of cancer in India, breast, cervix, colon and prostate cancer are most common and hence knowing its signs and symptoms is key to the management.
Dr Bhavna Parikh, Consultant Medical Oncologist of Bombay Hospital shares details about each of these cancers.
Download
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
ADVERTISEMENT
